DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,666,610 B2 Saitoh Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,666,610 B2 Saitoh Et Al USOO766661 OB2 (12) United States Patent (10) Patent No.: US 7,666,610 B2 Saitoh et al. (45) Date of Patent: Feb. 23, 2010 (54) EXPRESSING TRANSPORTERS ON VIRAL JP 11-172 1, 1999 ENVELOPES JP 2001-197846 T 2001 JP 2001-1394.96 5, 2005 (75) Inventors: Ryoichi Saitoh, Shizuoka (JP); KR 99071666 9, 1999 Toshihiko Ohtomo, Shizuoka (JP); WO WO97, 19919 6, 1997 Masayuki Tsuchiya, Shizuoka (JP) WO WO 98.46777 10, 1998 WO WOOO.28O16 5, 2000 (73) Assignee: Chugai Seiyaku Kabushiki Kaisha, WO WOO3/033024 4/2003 Tokyo (JP) WO WO 03/0476.21 6, 2003 WO WO 03/08311.6 A1 10, 2003 (*) Notice: Subject to any disclaimer, the term of this WO WOO3/104453 12/2003 patent is extended or adjusted under 35 U.S.C. 154(b) by 283 days. OTHER PUBLICATIONS (21) Appl. No.: 10/509,343 Hsu et al., Overexpression of human intestinal oligopeptide trans porter in mammalian cells via adenoviral transduction, 1998, Phar (22) PCT Filed: Mar. 28, 2003 maceutical Research, vol. 15, No. 9, pp. 1376-1381.* Garcia et al., cDNA cloning of MCT2, a second monocarboxylate (86). PCT No.: PCT/UP03/03975 transporter expressed in different cells than MCT1, 1995, Journal of Biological Chemistry, vol. 270, No. 4, pp. 1843-1849.* S371 (c)(1), Miyasaka, et al., Characterization of human taurine transporter (2), (4) Date: Jun. 21, 2005 expressed in insect cells using recombinant baculovirus, 2001, Pro tein Expression and Purification, vol. 23, pp. 389-397.* (87) PCT Pub. No.: WO03/083116 Hsu et al., Overexpression of human intestinal oligopeptide trans porter in mammalian cells via adenoviral transduction, 1998, Phar PCT Pub. Date: Oct. 9, 2003 maceutical Research, vol. 15, No. 9, pp. 1376-1381.* ATCC Web Catalog, "Tumor Cell Lines' www.atcc.org (2007), 15 (65) Prior Publication Data pageS. Boublik et al., “Eukaryotic Virus Display: Engineering the major US 2006/0O84119A1 Apr. 20, 2006 Surface Glycoprotein of the Autographa californica Nuclear Polyhedrosis Virus (ScNPV) for the Presentation of Foreign Proteins (30) Foreign Application Priority Data on the Virus Surface.” Biotechnology, 13 1079-1084 (1995). “Cancer Classification.” SEER Training Website, www.training.seer. Mar. 29, 2002 (JP) ............................. 2002-096038 cancer.gov/module cancer diseasefunti3 categories2 by histology (2005), 3 pages. (51) Int. Cl. Grever et al., “The National Cancer Institute: Cancer Drug Discovery GOIN 33/567 (2006.01) and Development Program.” Seminars in Oncology, 19(6): 622-638 C7H 2L/04 (2006.01) (1992). CI2P 2/06 (2006.01) Hefferon et al., “Host Cell receptor Binding by Baculovirus GP64 CI2N 5/06 (2006.01) and Kinetics of Virion Entry.” Virology, 258: 455-468 (1999). C07K I4/705 (2006.01) Kamada et al., “Production of GP64, the Major Envelope (52) U.S. Cl. ....................... 435/7.2:435/69.1; 435/348; Glycoprotein of Budded Baculovirus, Transgenic Mice and Induc 435/456; 530/350,536/23.5 tion of immunological Tolerance of GP64 Transgenic Mice,” Nihon (58) Field of Classification Search ....................... None Bunshi Seibutsu Gakkai Nenkai Program Koen Yoshishu, 26: 659 See application file for complete search history. (2003) (Translation Provided). Lu et al., “Characterization of a Truncated Soluble Form of the (56) References Cited Baculovirus (AcMNPV) Major Envelope Protein Gp64.” Protein Expression and Purification, 24: 196-201 (2002). U.S. PATENT DOCUMENTS 5,500,346 A 3/1996 Bright et al. (Continued) 5,849,525 A 12/1998 Hediger Primary Examiner Robert Landsman 6,270,978 B1 8/2001 Bright et al. ................. 435.7.1 Assistant Examiner Ian Dang 6,713,278 B1 3, 2004 Bouvier et al. (74) Attorney, Agent, or Firm Fish & Richardson P.C. 2005.0004227 A1 1/2005 Saitoh 2005/0222391 A1 10/2005 Kodama et al. (57) ABSTRACT 2005/0281825 A1 12/2005 Kodama et al. 2006, OO84119 A1 4/2006 Saitoh et al. 2006/0210569 A1 9/2006 Kodama et al. Methods for measuring transporter activity using budding 2008/0040820 A1 2/2008 Kodama et al. baculoviruses that do not express endogenous transporters on their envelope have a low background level and can measure FOREIGN PATENT DOCUMENTS the target activity with a high sensitivity. Such methods can be AU 96.76557 6, 1997 used to measure functional changes due to transporter SNPs EP 1142473 10, 2001 over a more extensive range of Substrates, and can be applied EP 1731 O32 12/2006 to tailor-made therapies. JP 6-261761 9, 1994 JP 8-1341.00 5, 1996 22 Claims, 4 Drawing Sheets US 7,666,610 B2 Page 2 OTHER PUBLICATIONS Sai Y. et al., “Immunolocalization and pharmacological relevance of oligopeptide transporter PepT1 in intestinal absorption off-lactam Monsma et al., “Identification of a Membrane Fusion Domain and an antibiotics”, FEBS Lett, vol. 392(1), pp. 25-29 (1996). Oligomerization Domain in the Baculovirus GP64 Envelope Fusion Basu SKetal., “Development and Utility of Anti-PepT1Anti-Peptide Protein.” Journal of Virology, 69: 2583-2595 (1995). Polyclonal Antibodies'. Pharmaceutical Research, vol. 15(2), pp. Monsma et al., “The GP64 Envelope Fusion Protein is an Essential 338-342 (1998). Baculovirus Protein Required for Cell-to-Cell Transmission of Infec Gonzalez DE et al., “An Olgiopeptide Transporter Is Expressed at tion.” Journal of Virology, 70: 4607-4616 (1996). High Levels in the Pancreatic Carcinona Cell Lines AsPc-1 and Ohtomo et al., “Generation of Anti-Human CCR Antagonistic Anti Capan-2', Cancer Res., vol. 58(3), pp. 519–525 (1998). bodies in GP64 Expressing and CCR2-Deficient Mice Using CCR2 Knutter et al., “A Novel Inhibitor of the Mammalian Peptide Trans Expressed Budded Baculovirus as an Antigen.” Nihon Bunshi porter PEPT1, Biochemistry, vol. 40(14), pp. 4454-4488 (2001). Seibutsu Gakkai Nenkai Program Koen Yoshishu, 26: 660 (2003) Mrsny R.J., “Olgiopeptide Transporters as Putative Therapeutic Tar (Translation Provided). gets for Cancer Cells'. Pharm Res. vol. 15(6), pp. 816-818 (1998). Seliger et al., “Analysis of the MHC Class I Antigen Presentation Nakanishi T. et al., "Cancer Cell-Targeted Drug Delivery Utilizing Machinery in Human Embryonal Carcinomas: Evidence for Defi Oligopeptide Transport Activity”. Int. J. Cancer, vol. 88(2), pp. 274 ciencies in TAP, LMP, and MHC Class I Expression and Their 280 (2000). Upregulation by IFN-Y.” Scandinavian Journal of Immunology, 46: Sugano K. et al., Quantitive Structure-Intestinal Permeability Rela 625-632 (1997) (Abstract). tionship of Benzamidine Analogue Thrombin Inhibitor, Bioorg Med. Suzuki et al., “Effects of Retinoic Acid on Lung Smooth Muscle Chem. Lett, vol. 10(17), pp. 1939-1942 (2000). Cells.” Meeting on Experimental Biology: Translating The Genome Terada T. et al., Tanpalcushitsu Kakusan Koso (Protein, nucleic acid (Apr. 17-21, 2004) as published in FASEB Journal, 18(4-5): 355-356 and enzyme), vol. 46(5), pp. 621-628 (2001) (Concise explanation in (2004) (Abstract). English enclosed). Tamura et al., "CD14 Transgenic Mice Expressing Membrane and Basu et al., “Screening of Anti-PepT1 Antibodies Using Indirect Soluble Forms: Comparisons of Levels of Sytokines and Lethalities ELISA.” Pharmaceutical Research, 13(9 Suppl.):S-37. Abstract No. APQ 1137 (1996). in Response to Lipopolysaccharide Between Transgenic and Non Blissard et al., “Location, Sequence, Transcriptional Mapping, and Transgenic Mice.” International Immunology, 11:333-339 (1999). Temporal Expression of the gp64 Envelope Glycoprotein Gene of the Watanabe et al., “Enhances Immune Responses in Transgenic Mice Orgyia pseudotsugata Multicapsid Nuclear Polyhedrosis Virus.” Expressing a Truncated Form of the Lymphocyte Semaphorin Virology, 170:537-555 (1989). CD100.” J. Immunol. 167: 4321-4328 (2001). Friedman et al., “Characterization of the Intestinal Transport Param Braunagel et al., “Autographe californica Nuclear Polyhedrosis eters for Small Peptide Drugs.” J. Control. Release, 13:141-146 Virus, PDV. and ECVViral Envelopes and Nucleocapsids: Structural (1990). Proteins, Antigens, Lipid and Fatty Acid Profiles'. Virology, vol. 202, Friedman et al., “Passive and Carrier-Mediated Intestinal Absorption pp. 315-320 (1994). Components of Two Angiotensin Converting Enzyme (ACE) Inhibi Grabherr et al., “Developments in the use of baculoviruses for the tor Prodrugs in Rats: Enalapril and Fosinopril.” Pharm. Res., 6:1043 Surface display of complex eukaryotic proteins’. Trends in Biology, 1047 (1989). vol. 19(6), pp. 231-235 (2001). Ganapathy et al., “Proton-coupled solute transport in the animal cell Marheineke et al., “Lipid composition of Spodoptera frugiperda plasma membrane.” Curr: Opin. Cell Biol. 3:695-701 (1991). (Sf9) and Trichoplusia ni (Tn) insect cells used for baculovirus infec Higgins, “ABC Transporters: From Microorganisms to Man.” Annu. tion’, FEBS vol. 441, pp. 49-52 (1998). Rev. Cell Biol., 8:67-113 (1992). Zhou X. et al., “Characterization of an oligopeptide transporter in Houdebine, “Transgenic animal bioreactors, Transgenic Res., renal lysosomes”. Biochim Biophys Acta, vol. 1466(1-2), pp. 372 9:305-320 (2000). 378 (2000). Kolb et al., “Insertion of a foreign gene into the f-casein locus by Lee VHL et al., "Biopharmaceutics of transmucosal peptide and Cre-mediated site specific recombination.” Gene, 227:21-31 (1999). protein drug administration: role of transport mechanisms with a Lariviere et al., “Transgenic Studies of Pain and Analgesia: Mutation focus on the involvement of PepT1'. J. Control Release, vol. 62(1-2), or Background Genotype?' J. Pharmacol. Exp. Ther. 297:467-473 pp. 129-140 (1999). (2001). Loisel TP et al., “Recovery of homogeneous and functional Leiter, "Mice with targeted gene disruptions or gene insertions for 32-adrenergic receptors from extracellular baculovirus particles'. diabetes research: problems, pitfalls, and potential Solutions.” Nat Biotechnol, vol. 15(12), pp. 1300-1304 (1997). Diabetologia, 45:296-308 (2002). Mangor J.T et al., “A GP64-Null Baculovirus Pseudotyped with Liang et al., “Human Intestinal H"/Peptide Cotransporter. Cloning, Vesicular Stomatitis Virus G Protein'. Journal of Virology, vol. 75(6), Functional Expression, and Chromosomal Localization.” J. Biol. pp. 2544-2556 (2001). Chem., 270:6456-6463 (1995).
Load more

Recommended publications
  • Potassium Channels in Epilepsy
    Downloaded from http://perspectivesinmedicine.cshlp.org/ on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Potassium Channels in Epilepsy Ru¨diger Ko¨hling and Jakob Wolfart Oscar Langendorff Institute of Physiology, University of Rostock, Rostock 18057, Germany Correspondence: [email protected] This review attempts to give a concise and up-to-date overview on the role of potassium channels in epilepsies. Their role can be defined from a genetic perspective, focusing on variants and de novo mutations identified in genetic studies or animal models with targeted, specific mutations in genes coding for a member of the large potassium channel family. In these genetic studies, a demonstrated functional link to hyperexcitability often remains elusive. However, their role can also be defined from a functional perspective, based on dy- namic, aggravating, or adaptive transcriptional and posttranslational alterations. In these cases, it often remains elusive whether the alteration is causal or merely incidental. With 80 potassium channel types, of which 10% are known to be associated with epilepsies (in humans) or a seizure phenotype (in animals), if genetically mutated, a comprehensive review is a challenging endeavor. This goal may seem all the more ambitious once the data on posttranslational alterations, found both in human tissue from epilepsy patients and in chronic or acute animal models, are included. We therefore summarize the literature, and expand only on key findings, particularly regarding functional alterations found in patient brain tissue and chronic animal models. INTRODUCTION TO POTASSIUM evolutionary appearance of voltage-gated so- CHANNELS dium (Nav)andcalcium (Cav)channels, Kchan- nels are further diversified in relation to their otassium (K) channels are related to epilepsy newer function, namely, keeping neuronal exci- Psyndromes on many different levels, ranging tation within limits (Anderson and Greenberg from direct control of neuronal excitability and 2001; Hille 2001).
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Transcriptomic Analysis of Native Versus Cultured Human and Mouse Dorsal Root Ganglia Focused on Pharmacological Targets Short
    bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Transcriptomic analysis of native versus cultured human and mouse dorsal root ganglia focused on pharmacological targets Short title: Comparative transcriptomics of acutely dissected versus cultured DRGs Andi Wangzhou1, Lisa A. McIlvried2, Candler Paige1, Paulino Barragan-Iglesias1, Carolyn A. Guzman1, Gregory Dussor1, Pradipta R. Ray1,#, Robert W. Gereau IV2, # and Theodore J. Price1, # 1The University of Texas at Dallas, School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, 800 W Campbell Rd. Richardson, TX, 75080, USA 2Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine # corresponding authors [email protected], [email protected] and [email protected] Funding: NIH grants T32DA007261 (LM); NS065926 and NS102161 (TJP); NS106953 and NS042595 (RWG). The authors declare no conflicts of interest Author Contributions Conceived of the Project: PRR, RWG IV and TJP Performed Experiments: AW, LAM, CP, PB-I Supervised Experiments: GD, RWG IV, TJP Analyzed Data: AW, LAM, CP, CAG, PRR Supervised Bioinformatics Analysis: PRR Drew Figures: AW, PRR Wrote and Edited Manuscript: AW, LAM, CP, GD, PRR, RWG IV, TJP All authors approved the final version of the manuscript. 1 bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Investigation of Candidate Genes and Mechanisms Underlying Obesity
    Prashanth et al. BMC Endocrine Disorders (2021) 21:80 https://doi.org/10.1186/s12902-021-00718-5 RESEARCH ARTICLE Open Access Investigation of candidate genes and mechanisms underlying obesity associated type 2 diabetes mellitus using bioinformatics analysis and screening of small drug molecules G. Prashanth1 , Basavaraj Vastrad2 , Anandkumar Tengli3 , Chanabasayya Vastrad4* and Iranna Kotturshetti5 Abstract Background: Obesity associated type 2 diabetes mellitus is a metabolic disorder ; however, the etiology of obesity associated type 2 diabetes mellitus remains largely unknown. There is an urgent need to further broaden the understanding of the molecular mechanism associated in obesity associated type 2 diabetes mellitus. Methods: To screen the differentially expressed genes (DEGs) that might play essential roles in obesity associated type 2 diabetes mellitus, the publicly available expression profiling by high throughput sequencing data (GSE143319) was downloaded and screened for DEGs. Then, Gene Ontology (GO) and REACTOME pathway enrichment analysis were performed. The protein - protein interaction network, miRNA - target genes regulatory network and TF-target gene regulatory network were constructed and analyzed for identification of hub and target genes. The hub genes were validated by receiver operating characteristic (ROC) curve analysis and RT- PCR analysis. Finally, a molecular docking study was performed on over expressed proteins to predict the target small drug molecules. Results: A total of 820 DEGs were identified between
    [Show full text]
  • Ion Channels 3 1
    r r r Cell Signalling Biology Michael J. Berridge Module 3 Ion Channels 3 1 Module 3 Ion Channels Synopsis Ion channels have two main signalling functions: either they can generate second messengers or they can function as effectors by responding to such messengers. Their role in signal generation is mainly centred on the Ca2 + signalling pathway, which has a large number of Ca2+ entry channels and internal Ca2+ release channels, both of which contribute to the generation of Ca2 + signals. Ion channels are also important effectors in that they mediate the action of different intracellular signalling pathways. There are a large number of K+ channels and many of these function in different + aspects of cell signalling. The voltage-dependent K (KV) channels regulate membrane potential and + excitability. The inward rectifier K (Kir) channel family has a number of important groups of channels + + such as the G protein-gated inward rectifier K (GIRK) channels and the ATP-sensitive K (KATP) + + channels. The two-pore domain K (K2P) channels are responsible for the large background K current. Some of the actions of Ca2 + are carried out by Ca2+-sensitive K+ channels and Ca2+-sensitive Cl − channels. The latter are members of a large group of chloride channels and transporters with multiple functions. There is a large family of ATP-binding cassette (ABC) transporters some of which have a signalling role in that they extrude signalling components from the cell. One of the ABC transporters is the cystic − − fibrosis transmembrane conductance regulator (CFTR) that conducts anions (Cl and HCO3 )and contributes to the osmotic gradient for the parallel flow of water in various transporting epithelia.
    [Show full text]
  • Effect of Genetic Variation on Salt, Sweet, Fat and Bitter Taste
    Effect of Genetic Variation on Salt, Sweet, Fat and Bitter Taste by Andre Dias A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Nutritional Sciences University of Toronto © Copyright by Andre Dias 2014 Effect of Genetic Variation on Salt, Sweet, Fat and Bitter Taste Andre Dias Doctor of Philosophy Department of Nutritional Sciences University of Toronto 2014 Abstract Background: Taste is one of the primary determinants of food intake and taste function can be influenced by a number of factors including genetics. However, little is known about the relationship between genetic variation, taste function, food preference and intake. Objective: To examine the effect of variation in genes involved in the perception of salt, sweet, fat and bitter compounds on taste function, food preference and consumption. Methods: Subjects were drawn from the Toronto Nutrigenomics and Health Study, a population of healthy men (n=487) and women (n = 1058). Dietary intake was assessed using a 196-item food frequency questionnaire (FFQ) and food preference was assessed using a 63-item food preference checklist. Subsets of individuals were phenotyped to assess taste function in response to salt (n=95), sucrose (n=95), oleic acid (n=21) and naringin (n=685) stimuli. Subjects were genotyped for Single Nucleotide Polymorphisms (SNPs) in candidate genes. Results: Of the SNPs examined in putative salt taste receptor genes (SCNN1(A, B, D, G), TRPV1), the rs9939129 and rs239345 SNPs in the SCNN1B gene and rs8065080 in the TRPV1 gene were associated with salt taste. In the TAS1R2 gene, the rs12033832 was associated with sucrose taste and sugar intake.
    [Show full text]
  • Chr Start End Size Gene Exon 1 69482 69600 118 OR4F5 1 1 877520
    #chr start end size gene exon 1 69482 69600 118 OR4F5 1 1 877520 877636 116 SAMD11 8 1 877807 877873 66 SAMD11 9 1 877934 878066 132 SAMD11 10 1 878067 878068 1 SAMD11 10 1 878070 878080 10 SAMD11 10 1 896670 896724 54 KLHL17 2 1 896726 896728 2 KLHL17 2 1 935267 935268 1 HES4 1 1 935271 935357 86 HES4 1 1 955548 955694 146 AGRN 1 1 955720 955758 38 AGRN 1 1 984242 984422 180 AGRN 24 1 984611 984629 18 AGRN 25 1 989928 989936 8 AGRN 35 1 1132946 1133034 88 TTLL10 13 1 1149358 1149397 39 TNFRSF4 1 1 1167654 1167713 59 B3GALT6 1 1 1167733 1167853 120 B3GALT6 1 1 1167878 1167908 30 B3GALT6 1 1 1181889 1182075 186 FAM132A 1 1 1200204 1200215 11 UBE2J2 2 1 1219462 1219466 4 SCNN1D 5 1 1223355 1223358 3 SCNN1D 12 1 1232009 1232018 9 ACAP3 15 1 1244308 1244320 12 PUSL1 2 1 1244321 1244327 6 PUSL1 2 1 1247601 1247603 2 CPSF3L 15 1 1290483 1290485 2 MXRA8 5 1 1290487 1290488 1 MXRA8 5 1 1290492 1290516 24 MXRA8 5 1 1290619 1290631 12 MXRA8 4 1 1291003 1291136 133 MXRA8 3 1 1292056 1292089 33 MXRA8 2 1 1334399 1334405 6 CCNL2 1 1 1355427 1355489 62 LOC441869 2 1 1355659 1355917 258 LOC441869 2 1 1361505 1361521 16 TMEM88B 1 1 1361523 1361525 2 TMEM88B 1 1 1361527 1361528 1 TMEM88B 1 1 1361635 1361636 1 TMEM88B 1 1 1361642 1361726 84 TMEM88B 1 1 1361757 1361761 4 TMEM88B 1 1 1362931 1362956 25 TMEM88B 2 1 1374780 1374838 58 VWA1 3 1 1374841 1374842 1 VWA1 3 1 1374934 1375100 166 VWA1 3 1 1389738 1389747 9 ATAD3C 4 1 1389751 1389816 65 ATAD3C 4 1 1389830 1389849 19 ATAD3C 4 1 1390835 1390837 2 ATAD3C 5 1 1407260 1407331 71 ATAD3B 1 1 1407340 1407474
    [Show full text]
  • Ion Channels
    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
    [Show full text]
  • Identification of Key Pathways and Genes in Dementia Via Integrated Bioinformatics Analysis
    bioRxiv preprint doi: https://doi.org/10.1101/2021.04.18.440371; this version posted July 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Identification of Key Pathways and Genes in Dementia via Integrated Bioinformatics Analysis Basavaraj Vastrad1, Chanabasayya Vastrad*2 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karnataka, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2021.04.18.440371; this version posted July 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract To provide a better understanding of dementia at the molecular level, this study aimed to identify the genes and key pathways associated with dementia by using integrated bioinformatics analysis. Based on the expression profiling by high throughput sequencing dataset GSE153960 derived from the Gene Expression Omnibus (GEO), the differentially expressed genes (DEGs) between patients with dementia and healthy controls were identified. With DEGs, we performed a series of functional enrichment analyses. Then, a protein–protein interaction (PPI) network, modules, miRNA-hub gene regulatory network and TF-hub gene regulatory network was constructed, analyzed and visualized, with which the hub genes miRNAs and TFs nodes were screened out. Finally, validation of hub genes was performed by using receiver operating characteristic curve (ROC) analysis.
    [Show full text]
  • Targeting EZH2 Increases Therapeutic Efficacy of PD-1 Check-Point Blockade in Models of Prostate Cancer Supplement Figures and T
    Targeting EZH2 Increases Therapeutic Efficacy of PD-1 Check-Point Blockade in Models of Prostate Cancer Supplement Figures and Tables 1 Fig. S1. (A) Schema and genotyping PCR example for the creation of EM and EMC genetically engineered mice. (B) Three-dimensional PCa organoids generated from EM mice (without PSACreERT2) alleles. When treated with tamoxifen, demonstrates no loss of H3K27me3 or EDU staining, indicating specificity of tamoxifen-PSACreERT2 mediated deletion of the Ezh2 set domain. (C) Principle component analysis (PCA) following chemical and genetic inhibition of Ezh2 catalytic function results in significant changes in gene expression. 2 Fig. S2. (A) A 29-gene signature derived from Fig. 1C demonstrates complete independence from a previously published polycomb repression signature. (B) Our 29 gene signature demonstrates significant correlation with a previously published polycomb repression signature in 2 independent human PCa gene expression datasets. (C) EZH2 activity is not determined by EZH2 mRNA expression. 3 Fig. S3. A 29-gene signature derived from Fig 1C was used to generate signature scores for each patient within four independent human prostate cancer RNA-seq datasets. Patients were ranked highest score to lowest score and subject to quartile separation. First (blue) and fourth (red) quartiles were analyzed by supervised clustering to demonstrate expression differences within patients with most lowest EZH2 activity and most highest EZH2 activity. 4 Fig. S4. Genes representing IFN signaling (STAT1, IRF9), Th1 chemokines (CXCL10, CXCL11), and MHC Class I molecules (B2M, HLA-A) were shown to be enriched in PCa patients with low EZH2 activity. 5 Fig. S5. Treatment of 22Rv1 human 2D cell lines with the demonstrated conditions for 96 hours show that EZH2 inhibition increases expression of dsRNA (green = dsRNA, blue = nuclei).
    [Show full text]
  • Download (PDF)
    Supplemental Information Biological and Pharmaceutical Bulletin Promoter Methylation Profiles between Human Lung Adenocarcinoma Multidrug Resistant A549/Cisplatin (A549/DDP) Cells and Its Progenitor A549 Cells Ruiling Guo, Guoming Wu, Haidong Li, Pin Qian, Juan Han, Feng Pan, Wenbi Li, Jin Li, and Fuyun Ji © 2013 The Pharmaceutical Society of Japan Table S1. Gene categories involved in biological functions with hypomethylated promoter identified by MeDIP-ChIP analysis in lung adenocarcinoma MDR A549/DDP cells compared with its progenitor A549 cells Different biological Genes functions transcription factor MYOD1, CDX2, HMX1, THRB, ARNT2, ZNF639, HOXD13, RORA, FOXO3, HOXD10, CITED1, GATA1, activity HOXC6, ZGPAT, HOXC8, ATOH1, FLI1, GATA5, HOXC4, HOXC5, PHTF1, RARB, MYST2, RARG, SIX3, FOXN1, ZHX3, HMG20A, SIX4, NR0B1, SIX6, TRERF1, DDIT3, ASCL1, MSX1, HIF1A, BAZ1B, MLLT10, FOXG1, DPRX, SHOX, ST18, CCRN4L, TFE3, ZNF131, SOX5, TFEB, MYEF2, VENTX, MYBL2, SOX8, ARNT, VDR, DBX2, FOXQ1, MEIS3, HOXA6, LHX2, NKX2-1, TFDP3, LHX6, EWSR1, KLF5, SMAD7, MAFB, SMAD5, NEUROG1, NR4A1, NEUROG3, GSC2, EN2, ESX1, SMAD1, KLF15, ZSCAN1, VAV1, GAS7, USF2, MSL3, SHOX2, DLX2, ZNF215, HOXB2, LASS3, HOXB5, ETS2, LASS2, DLX5, TCF12, BACH2, ZNF18, TBX21, E2F8, PRRX1, ZNF154, CTCF, PAX3, PRRX2, CBFA2T2, FEV, FOS, BARX1, PCGF2, SOX15, NFIL3, RBPJL, FOSL1, ALX1, EGR3, SOX14, FOXJ1, ZNF92, OTX1, ESR1, ZNF142, FOSB, MIXL1, PURA, ZFP37, ZBTB25, ZNF135, HOXC13, KCNH8, ZNF483, IRX4, ZNF367, NFIX, NFYB, ZBTB16, TCF7L1, HIC1, TSC22D1, TSC22D2, REXO4, POU3F2, MYOG, NFATC2, ENO1,
    [Show full text]